|
1. Vrablik J, Masata J, Jedlickova A, Hajicková M. [Prospective study the prevalence of different candida strains and their sensitivity to different antimycotic treatment in women with vulvovaginal candidiasis]. Ceska Gynekol 2007; 72(1): 27-32. 2. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol 1991; 165(4 Pt 2): 1168-76. 3. Aalei B, Touhidi A. Prevalence of candida vaginits among symptomatic patients in kerman. J Qazvin Univ Med Sci 2000; 4(1): 42-8. [in Persian] 4. Mosadegh M, Dehmoubed Sharifabadi A, Nasiri P, Esmaeili S, Naghibi F. The study of phytochemical, antifungal and antibacterial effects of teucrium polium and cichourium intybus. Scientific J Kurdistan Univ Med Sci 2002; 7(1): 1-6. [in Persian] 5. Biggs WS, Williams RM. Common gynecologic infections. Prim Care 2009; 36(1): 33-51, viii. 6. Vacheva-Dobrevski R, Kovachev S, Nacheva A, Stoev S, Vasilev N. Comparative study of itraconazole and fluconazole therapy in vaginal candidosis. Akush Ginekol (Sofiia) 2004; 43(1): 20-3. 7. Quan M. Vaginitis: meeting the clinical a challenge. Clin Cornerstone 2000; 3(1): 36-47. 8. Handa V, Stice CW. Fungal culture findings in cyclic vulvitis. Obstet Gynecol 2000; 96(2): 301-3. 9. Oriel JD, Partridge BM, Denny MJ, Coleman JC. Genital yeast infections. Br Med J 1972; 4(5843): 761-4. 10. Cristiano L, Rampello S, Noris C, Valota V. Bacterial vaginosis: prevalence in an Italian population of asymptomatic pregnant women and diagnostic aspects. Eur J Epidemiol 1996; 12(4): 383-90. 11. Ventolini G, Baggish MS, Walsh PM. Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy. J Reprod Med 2006; 51(6): 475-8. 12. Khoursandi M, Modares Gilani M, Khosravi AR. Treatment and recurrence of vaginal candidiasis after oral & Vulvovaginal Candidiasis and intravaginal treatment. J Qazvin Univ medical Sci 2000; 4(2): 25-9. [in Persian] 13. Horowitz BJ. Mycotic vulvovaginitis: abroad overview. Am J Obstet Gynecol 1991; 165(4 Pt 2): 1188-92. 14. Faye-Kette YH, Kouassi AA, Sylla-Koko DF, Kacou-N'-Douba A, Akoua-Koffi G, Acho YB, et al. [Prevalence of 4 agents of sexually transmitted diseases in leukorrhea in Abidjan (Ivory Coast)]. Bull Soc Pathol Exot 1993; 86(4): 245-7. 15. Ferris DG, Hendrich J, Payne PM, Getts A, Rassekh R, Mathis D, et al. Office laboratorydiagnosis of vaginitis. Clinician-performed testscompared with a rapid nucleic acidhybridization test. J Fam Pract 1995; 41(6):575-81. 16. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43(5): 2155-62. 17. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but donot cause acute cytotoxicity. Small 2005; 1(3): 325–7. 18. Salata O. V. (2004).Application & Properties of nanoparticles in biology and medicine.j. nano biotechnology.2 (3) : 1-8. 19. Pfaller M, Messer S. Coparision of visual and spectrophotometris methods of MIC and point determinations by using broth microdilution methods to test five antifungal agents including the new triazol. J Clin Microbiol 1995; 33: 1094-7. 20. Nccls. Methods for antifungal disc diffusion suseptibility testing of yeast, Approved Guideline NCELS Document M44-A. NCCLS. Wayne. Pennsylranias; 2004. 21. Chwalibog A, Sawosz E, Hotowy A, Szeliga J, Mitura S, Mitura K, et al. Visualization of interaction between inorganic nanoparticles and bacteria or fungi. Int J Nanomedicine 2010; 6(5): 1085-94. 22. Zhao G, Stevens SE Jr. Multiple parameters for the comprehensive evaluation of the susceptibility of Escherichia coli to the silver ion. Biometals 1998; 11(1): 27–32. 23. Jebali A, Hajjar FH, Pourdanesh F, Hekmatimoghadam S, Kazemi B, Masudi M, et al. Silver and gold nanostructures: antifungal property of different shapes of these nanostructures on Candida species. Med Mycol 2014; 52(1): 65-72. 24. Martinez-Gguterrez F, Olive PL, Banuelos A. Characterization and evalution of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine 2010; 6(5): 681-8. 25. Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Developmant of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010; 17(6): 585-94. 26. Zheng Y, Sache L. Gold nanoparticles enhance DNA damage induced by anti-cancer drugs and radiation. Radiat Res 2009; 172(1): 114–9. 27. Kim KJ, Sung WS, Suh BK, Moon SK, Choi JS, Kim JG, et al. Antifungal activity and mode of action of silver nano-particles on Candida albicans. Biometals 2009; 22(2): 235-42. 28. Wani IA, Ahmad T, Manzoor N. Size and shape dependant antifungal activity of gold nanoparticles: a case study of Candida. Colloids Surf B Biointerfaces 2013; 101(1): 162-70. 29. Zawrah MF, El-Moez SA, Center D. Antimicrobial activities of gold nanoparticles against major foodborne pathogens. Life Sci J 2011; 8(4): 37-44. 30. Nasrollahi A, Pourshamsian KH, Mansourkiaee P. Antifungal activity of silver nanoparticles on some os fungi. Int J Nano Dim 2011; 1(3): 233-9.
|
_-_Copy.png)
.png){kind=logo}
